What does ORBITA CTO tell us about CTO PCI?

Chronic total occlusions (CTOs) remain a key area of uncertainty in interventional cardiology, particularly regarding symptom improvement after PCI.

In this EuroPCR 2026 interview, John Davies and Sarosh Khan discuss the ORBITA CTO trial and its implications for clinical practice.

As the first double-blind, placebo-controlled randomised trial in CTO PCI, ORBITA CTO evaluates whether symptom relief, especially angina frequency, truly exceeds placebo in carefully selected patients.

The discussion highlights the study’s design, key findings, and what they mean for CTO operators and clinicians managing patients with CTOs in everyday practice.

Watch now to find out more!

This interview was filmed at EuroPCR 2026: see more videos here.